{"id":20389,"date":"2022-07-04T17:24:40","date_gmt":"2022-07-04T15:24:40","guid":{"rendered":"https:\/\/www.izb-online.de\/sirion-biotech-auf-expansionskurs-fuer-die-zell-und-gentherapie\/"},"modified":"2022-07-05T10:23:57","modified_gmt":"2022-07-05T08:23:57","slug":"sirion-biotech-auf-expansionskurs-fuer-die-zell-und-gentherapie","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/sirion-biotech-on-expansion-course-for-cell-and-gene-therapy\/","title":{"rendered":"SIRION Biotech on expansion course for cell and gene therapy"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

SIRION Biotech on expansion course for cell and gene therapy<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Inauguration ceremony of the new research site for virus vectors in Gr\u00e4felfing near Munich, Germany[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]July 2022[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”20386″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Sabine Ott, Senior Vice President BD & Licensing SIRION Biotech, Friedrich Neuhaus, Aumenta GmbH, Katrin Schneider, Senior VP Global Business, SIRION Biotech[\/vc_column_text][vc_single_image image=”20378″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Christian Thirion, CEO SIRION Biotech and Bryan Kipp, VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1656948321073{margin-top: 12px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

“Global demand for high-quality viral vectors is increasing and existing development capacity is scarce, so SIRION Biotech’s tripling of capacity in Gr\u00e4felfing is attracting global attention. We have already opened a new research lab in Heidelberg in 2020 and plan to do something similar in Boston in early 2023.”<\/h6>\n

Dr. Christian Thirion
\nCEO SIRION Biotech<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Gr\u00e4felfing near Munich, June 23, 2022: <\/strong>Munich-based start-up SIRION Biotech, whose success story began in 2006 at the Martinsried Biotechnology Innovation and Start-up Center (IZB), moved into its new research and administration center in Gr\u00e4felfing near Munich in January. With this expansion, SIRION Biotech triples its laboratory and office space. The goal is to advance the use of viral vectors in the development of vaccines and therapies. With the market approval of AstraZeneca’s COVID vaccine, viral vectors have become widely known. Thanks to novel gene and cell therapies using viral vectors, millions of patients worldwide can hope for therapies for either their rare genetic diseases or diseases triggered by unfavorable mutations as part of aging.<\/p>\n

“Global demand for high-quality viral vectors is increasing and existing development capacity is scarce, so SIRION Biotech’s tripling of capacity in Gr\u00e4felfing is attracting global attention. We have already opened a new research lab in Heidelberg in 2020 and plan to do something similar in Boston in early 2023,” said Dr. Christian Thirion, CEO SIRION Biotech.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” css=”.vc_custom_1656948326448{margin-top: 12px !important;}”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”20380″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]G\u00e4ste der Einweihungsfeier SIRION Biotech\/Guests of the opening ceremony SIRION Biotech[\/vc_column_text][vc_single_image image=”20384″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dieter Lingelbach, COO SIRION Biotech[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]The Free State of Bavaria is proud of its early support for young life science companies, which has already created thousands of high-tech jobs. More than a hundred life science start-ups have been supported by various state agencies over the past 20 years. SIRION Biotech now employs more than 65 people, most of them in Munich. SIRION Biotech’s new laboratories can accommodate more than 120 employees working in the fields of molecular biology, cell culture, virus purification and analysis.<\/p>\n

SIRION Biotech has developed over 7,000 such vectors to date for more than 200 therapy developers worldwide. Its technologies are used in over 20 clinical programs in the U.S., Europe and China. The company now has offices in Boston and Paris and works closely with representatives in Japan, Korea and Israel.<\/p>\n

The globally successful biotech start-up was acquired in September 2021 by PerkinElmer, which values the company’s potential in developing viral vector tools for cell and gene therapy providers. PerkinElmer employs more than 14,000 people and offers extensive expertise in diagnostics, medical research, and environmental and food analysis through innovative detection, imaging, and informatics systems. PerkinElmer is based in the U.S. and is listed on NASDAQ. PerkinElmer is expanding its services and support for cell and gene therapy developers and sees great opportunities for SIRION Biotech’s advanced viral technologies, particularly through the expansion of facilities at its new site in Gr\u00e4felfing near Munich.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” css=”.vc_custom_1656948331312{margin-top: 12px !important;}”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”20376″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Christian Thirion, CEO SIRION Biotech; Susanne Simon, Head of Public Relations IZB; Dr. Peter Hanns Zobel, CEO IZB (v.l.n.r.)[\/vc_column_text][vc_single_image image=”20382″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 VP\/GM Life Sciences Strategy & Integration at PerkinElmer, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Kerstin Schreyer, Staatsministerin a. D. und Vorsitzenden des Ausschusses f\u00fcr Wirtschaft, Landesentwicklung, Energie, Digitalisierung und Medien[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n